文献速递头颈部肿瘤放疗放疗物理与技术

口咽癌每日自适应放疗:1.5T MRI-linac 的 ATS 工作流程初步结果及与螺旋断层放疗的比较

Adaptive radiotherapy for oropharyngeal cancer with daily adapt-to-shape workflow on 1.5 T MRI-linac: Preliminary outcomes and comparison with helical tomotherapy.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-03-25

该研究前瞻性分析了 34 例在 Unity® MR-linac 上接受每日自适应放疗(ATS 工作流程)的口咽鳞状细胞癌(OPSCC)根治性放化疗患者,并与 34 例接受 Radixact® 螺旋断层放疗的匹配患者进行比较。结果显示 Unity® 组放疗后 3 个月 KPS 更高(87.67 vs 83.87;p=0.038),放疗期间住院率更低(35.3% vs 64.1%;p=0.015),2 级口干症和味觉障碍发生率虽较低但无统计学显著性。两种技术的局部完全缓解率均较高。

要点

  • Unity® MR-linac 的 ATS 工作流程用于 OPSCC 根治性放化疗是可行的。
  • 放疗后 3 个月 Unity® 组 KPS 显著高于 Radixact® 组(87.67 vs 83.87;p=0.038)。
  • 放疗期间 Unity® 组住院率显著低于 Radixact® 组(35.3% vs 64.1%;p=0.015)。

核心结论

  • 分析结果支持 ATS MR-linac 工作流程用于 OPSCC 根治性放化疗的可行性。
  • 与螺旋断层放疗相比,Unity® 治疗导致显著更低的住院率和放疗后 3 个月更高的 KPS。
  • Unity® 组 2 级口干症和味觉障碍发生率无显著降低,两种技术的局部控制结果均较优。

研究设计与样本

  • 前瞻性分析 2022 年 9 月至 2024 年 5 月单中心连续 34 例接受 Unity® MR-linac 每日自适应放疗(ATS 工作流程)的 OPSCC 根治性放化疗患者。
  • 回顾性获取 34 例特征相似、接受 Radixact® 螺旋断层放疗的患者作为比较队列。

主要发现

  • 两组特征均衡;放疗结束时 MRI-linac 组最大毒性 ≥2 级发生率边缘性更高(p=0.049),但放疗后 1 个月更低(76.5% vs 91.2%;p=0.257)。
  • Unity® 组放疗后 1 个月和 3 个月 ≥2 级口干症和味觉障碍发生率无显著降低。
  • Radixact® 组在 20 次分次时和放疗结束时住院率更高(64.1% vs 35.3%;p=0.015)。
  • Unity® 组放疗后 3 个月平均 KPS 更高(87.67 vs 83.87;p=0.038)。
  • 中位随访 361.5 天,Unity® 组局部完全缓解率 93.6%,Radixact® 组 96.8%。

关键数值与推荐

  • 放疗结束时最大毒性 ≥2 级发生率组间比较 p=0.049。
  • 放疗后 1 个月最大毒性 ≥2 级发生率 Unity® 组 76.5% vs Radixact® 组 91.2%(p=0.257)。
  • 20 次分次时和放疗结束时住院率 Unity® 组 35.3% vs Radixact® 组 64.1%(p=0.015)。
  • 放疗后 3 个月平均 KPS Unity® 组 87.67 vs Radixact® 组 83.87(p=0.038)。
  • 中位随访 361.5 天,局部完全缓解率 Unity® 组 93.6% vs Radixact® 组 96.8%。

临床怎么用

  • 对于 OPSCC 根治性放化疗,可考虑采用 Unity® MR-linac 的 ATS 每日自适应工作流程。
  • 该工作流程可能与更低的住院率和放疗后 3 个月更高的 KPS 相关。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: MR-linac could offer several advantages for radical radiochemotherapy (RCHT) in oropharyngeal squamous cell carcinoma (OPSCC) patients. Currently, only a few case series have been published and no comparison with other techniques have been performed. METHODS: Data of 34 consecutive patients treated from September 2022 to May 2024 at a single Institution with RCHT on Unity® MR-linac for OPSCC with daily adaptive radiotherapy (RT) according to the adapt-to-shape (ATS) workflow were prospectively analyzed. A comparative cohort of 34 patients with similar characteristics treated with helical treatment on Radixact® was retrieved. RESULTS: Characteristics were well balanced across the two groups. Maximal toxicity grade ≥2 rate was borderline higher at RT end in MRI-linac group (p 0.049), but lower one month after RT (76.5 % vs 91.2 %; p = 0.257).Non-significantly lower rates of grade ≥2 xerostomia and dysgeusia were reported in Unity® group one and three months after RT. Higher rates of hospitalizations were reported in Radixact group at 20 fractions and at RT end (64.1 % vs 35.3 %; p = 0.015). Mean Karnofsky performance status (KPS) was higher in Unity group three months after RT (87.67 vs 83.87; p = 0.038).After a median follow up of 361.5 days, local complete response was reported for 93.6 % of patients treated with Unity® and 96.8 % of patients treated with Radixact®. CONCLUSIONS: Results of this analysis support the feasibility of an ATS MR-linac workflow for RCHT in OPSCC. Compared with tomotherapy, treatment with Unity® resulted in significantly lower rates of hospitalization and higher KPS three months after RT. Grade 2 xerostomia and dysgeusia rates were non-significantly lower in Unity group. Optimal results in terms of local control were reported for both techniques.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Guerini AE, Buglione M, Nici S, et al. Adaptive radiotherapy for oropharyngeal cancer with daily adapt-to-shape workflow on 1.5 T MRI-linac: Preliminary outcomes and comparison with helical tomotherapy. Clin Transl Radiat Oncol. 2025. PMID: 40231325. doi:10.1016/j.ctro.2025.100950

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。